Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

CytoDyn Inc. (OTC:CYDY) Stock Surges 11%: Should You Buy?

If you are looking into those stocks that clocked strong gains on Tuesday, then it is difficult to look past CytoDyn Inc. (OTC:CYDY), which recorded gains of 11% amidst strong interest.

CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

The biotech company involved in the development of leronlimab, an antagonist with multiple therapeutic indications, announced yesterday the preliminary results review from the preclinical study that had been conducted in collaboration with SMC Laboratories. SMC Laboratories is a specialist in conducting preclinical studies for efficacy of medicines through a range of inflammation and fibrosis models in mice.

At the conclusion of its study, SMC Laboratories concluded that monotherapy with leronlimab showed statistically significant reduction in fibrosis in comparison to the IgG4 control arm isotope. It also appeared to display dose-centric antifibrotic activity. Leronlimab 700 mg performed better in the reversal of liver fibrosis in comparison to leronlimab 350 mg.

CEO Comment

The Chief Executive Officer of CytoDyn, Dr. Jacob Lalezari, noted that the initial results were highly exciting and also reinforced the company’s belief that the product could be beneficial to patients beset with a number of medical concerns. He went on to note that further research was going to be conducted in order to confirm the findings from the study.

Traders Notes

Published by Madison Hall

After graduating from the University of Buffalo, Madison gained a real interest in the markets. She tends to be a swing trader and enjoys Pilates and yoga in her downtime.

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Subscribe to the Wall Street Grapevine Newsletter Now and Get Free Alerts On Stocks Ready To Explode!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
*By submitting your information you agree to the terms of our Privacy Policy. You will receive the DRP Journal newsletter, and third party offers. You can unsubscribe anytime by selecting unsubscribe at the bottom of our emails.